155 related articles for article (PubMed ID: 29970298)
1. Low-dose-rate brachytherapy for prostate cancer in renal transplant recipients.
Rivero-Belenchón I; Osmán-García I; Congregado-Ruíz CB; Cabrera-Roldán P; Jiménez-Torres MJ; Baeza-Trujillo M; Lendínez-Cano G; Conde-Sánchez JM; Argüelles-Salido E; Ortiz-Gordilo MJ; Medina-López RA
Brachytherapy; 2018; 17(5):808-815. PubMed ID: 29970298
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Feasibility of Low-Dose Rate Brachytherapy for Prostate Cancer in Renal Transplant Recipients.
Iizuka J; Hashimoto Y; Hashimoto Y; Kondo T; Takagi T; Nozaki T; Shimizu T; Akimoto T; Ishida H; Karasawa K; Tanabe K
Transplant Proc; 2016 Apr; 48(3):910-3. PubMed ID: 27234765
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose-Rate and High-Dose-Rate Brachytherapy for Localized Prostate Cancer in ABO-Incompatible Renal Transplant Recipients.
Tasaki M; Kasahara T; Kaidu M; Kawaguchi G; Hara N; Yamana K; Maruyama R; Takizawa I; Ishizaki F; Saito K; Nakagawa Y; Ikeda M; Umezu H; Nishiyama T; Aoyama H; Tomita Y
Transplant Proc; 2019 Apr; 51(3):774-778. PubMed ID: 30979463
[TBL] [Abstract][Full Text] [Related]
4. Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel.
Hevia V; Boissier R; Rodríguez-Faba Ó; Fraser-Taylor C; Hassan-Zakri R; Lledo E; Regele H; Buddde K; Figueiredo A; Olsburgh J; Breda A
Eur Urol Focus; 2018 Mar; 4(2):153-162. PubMed ID: 29921544
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and urological toxicity of low-dose-rate brachytherapy (LDR-BT) as monotherapy in localized prostate cancer.
Vuolukka K; Auvinen P; Palmgren JE; Voutilainen T; Aaltomaa S; Kataja V
Brachytherapy; 2019; 18(5):583-588. PubMed ID: 31227400
[TBL] [Abstract][Full Text] [Related]
7. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
8. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
9. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
10. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
12. Iodine-125 prostate seed brachytherapy in renal transplant recipients: an analysis of oncological outcomes and toxicity profile.
Beydoun N; Bucci J; Malouf D
J Contemp Brachytherapy; 2014 Mar; 6(1):15-20. PubMed ID: 24790617
[TBL] [Abstract][Full Text] [Related]
13. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Feasibility of Intensity-Modulated Radiation Therapy for Prostate Cancer in Renal Transplant Recipients.
Iizuka J; Hashimoto Y; Hashimoto Y; Kondo T; Takagi T; Nozaki T; Shimizu T; Akimoto T; Ishida H; Karasawa K; Tanabe K
Transplant Proc; 2016 Apr; 48(3):914-7. PubMed ID: 27234766
[TBL] [Abstract][Full Text] [Related]
15. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
16. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R
Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381
[TBL] [Abstract][Full Text] [Related]
17. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
18. Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (≤60 years) with localized prostate cancer.
Winoker JS; Omidele OO; Stock RG; Stone NN
Brachytherapy; 2019; 18(2):192-197. PubMed ID: 30635196
[TBL] [Abstract][Full Text] [Related]
19. Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.
Echevarria MI; Naghavi AO; Abuodeh YA; Ahmed KA; Chevere C; Fernandez D; Yamoah K
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):378-382. PubMed ID: 28871987
[TBL] [Abstract][Full Text] [Related]
20. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.
Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS
Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
